drugset / Trial / NCT01313572

Study of the Safety and Efficacy of Apadenoson for Detection of Myocardial Perfusion Defects Using SPECT MPI

NCT01313572

Phase 3 Terminated 197 enrolled Forest Laboratories PPD Development, LP · collab
RandomizedCrossoverTriple-blindDiagnostic

Summary

The purpose of this study is to see whether apadenoson is as effective as adenosine when used as a pharmacological stress agent in myocardial SPECT-imaging (SPECT-MPI)to detect defects in the supply of blood to the heart muscle (myocardial perfusion defects). The study will also look at whether apadenoson is better tolerated than adenosine when used in SPECT-MPI.

Timeline

Start
2011-08
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Adenosine Small molecule 140 ug/kg Intravenous
Subject Apadenoson Small molecule 100 ug Intravenous
Subject Apadenoson Small molecule 150 ug Intravenous